Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Somaieh Hedayat
Observed names:
Hedayat, Somaieh,
S. Hedayat
Institution:
Institute of Cancer Research
Observed institutions:
University of Copenhagen,
Royal Marsden NHS Foundation Trust,
Institute of Cancer Research,
Breast Cancer Now,
Cancer Research UK,
Biogipuzkoa Health Research Institute,
Royal Marsden Hospital,
NIHR Biomedical Research Centre at The Royal Marsden and the ICR
show all 8
ORCID:
0000-0002-3547-9184
Observed ORCID:
0000-0002-3547-9184
OpenAlex ID:
A5076248362
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
2018
·
Georgios Vlachogiannis
, Somaieh Hedayat
, et al.
·
Science
·
2,315
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
2018
·
Khurum H. Khan
, David Cunningham
, et al.
·
Cancer Discovery
·
241
MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma
2017
·
Andrea Lampis
, Pietro Carotenuto
, et al.
·
Gastroenterology
·
123
PDF
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells
2016
·
Roberta Ferraldeschi
, Jonathan Welti
, et al.
·
Cancer Research
·
103
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
2017
·
Khurum Khan
, Mihaela Rata
, et al.
·
Gut
·
78
PDF
HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells
2022
·
Kamolporn Amornsupak
, Suyanee Thongchot
, et al.
·
BMC Cancer
·
65
PDF
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target
2018
·
Jacqueline H.L. Fok
, Somaieh Hedayat
, et al.
·
Clinical Cancer Research
·
58
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
2020
·
Elizabeth C Smyth
, Georgios Vlachogiannis
, et al.
·
Gut
·
50
PDF
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial
2019
·
Gayathri Anandappa
, Andrea Lampis
, et al.
·
Clinical Cancer Research
·
50
PDF
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
2023
·
Philip Bland
, Harry Saville
, et al.
·
Nature Genetics
·
49
PDF
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
2024
·
Somaieh Hedayat
, Luciano Cascione
, et al.
·
Clinical Cancer Research
·
46
Modulation of Biliary Cancer Chemo‐Resistance Through MicroRNA‐Mediated Rewiring of the Expansion of CD133+ Cells
2019
·
Pietro Carotenuto
, Somaieh Hedayat
, et al.
·
Hepatology
·
42
PDF
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage
2021
·
Pietro Carotenuto
, Francesco Amato
, et al.
·
Nature Communications
·
41
PDF
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease
2019
·
Giampiero Colombano
, John J. Caldwell
, et al.
·
Journal of Medicinal Chemistry
·
34
PDF
MicroRNAs as mediators of drug resistance mechanisms
2020
·
Andrea Lampis
, Jens C Hahne
, et al.
·
Current Opinion in Pharmacology
·
25
MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer
2021
·
Andrea Lampis
, Jens C. Hahne
, et al.
·
Cell Death and Differentiation
·
24
PDF
Abstract 2433: In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.
2013
·
Roberta Ferraldeschi
, Somaieh Hedayat
, et al.
·
Cancer Research
·
6
Patient-Derived Organoids: Promises, Hurdles and Potential Clinical Applications
2020
·
S. Hedayat
, N. Valeri
·
Clinical Oncology
·
5
Circulating miR-652-3p as a biomarker of drug resistance in metastatic colorectal cancer patients
2019
·
S. Hedayat
, A. Lampis
, et al.
·
Annals of Oncology
·
1
Abstract LB-305: Circulating miR-652-3p as a biomarker of resistance to regorafenib in metastatic colorectal cancer patients
2019
·
Somaieh Hedayat
, Khurum Khan
, et al.
·
Cancer Research
·
1
Data from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
2024
·
Somaieh Hedayat
, Luciano Cascione
, et al.
Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
2024
·
Somaieh Hedayat
, Luciano Cascione
, et al.
Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
2024
·
Somaieh Hedayat
, Luciano Cascione
, et al.
Supplementary Figure S6 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
2024
·
Somaieh Hedayat
, Luciano Cascione
, et al.
Supplementary Figure S3 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer
2024
·
Somaieh Hedayat
, Luciano Cascione
, et al.
Show more works
View as search
Works count:
61
Citation count:
3,357
H-index:
16
I10-index:
16
Year
Topic
Type